iNtRON Bio has conducted the world’s first clinical trial with an endolysin-based drug, which is undergoing phase 2 study and will be a ‘First-in-class’ antibacterial with distinct mode of action. iNtRON Bio will successfully develop ‘blockbuster’ and ‘moral-buster’ new drug.
iNtRON wants to be a R&D company for human’s public health based on the belief that health is basis of a happy life. Since iNtRON will be the first mover, it will not be easy, but iNtRON will make it happen.
Technologies
Pipelines
We are aiming new and high
Past, Present, and iNtRON
iNtRON has a passion for the R&D of new drug which can contribute to resolve a global conundrum. We have been doing open innovation with new, creative, and flexible mind-set. We will not stop R&D that can give a hope for despaired patients.
Technologies
Pipelines
iNtODEWORLD
A Game Changer in Antibacterial Drugs for Superbugs and Persister Cells
We are committed to finding effective treatment for life-threatening infectious diseases.
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
iNtRON Biotechnology, Inc.
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerates development speed after the IPO in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
The Indirect Cause of Mortality in Covid-19 The journal ‘Phage’ recently published a review suggesting the use of bacteriophages in patients with severe Covid-19. According to the review, the indirect cause of mortality in patients with Covid-19 is due to miscommunication between the innate and......
Mutations in the Pandemic Influenza Virus Since seasonal influenza virus is constantly mutating through antigenic shift, it is necessary to develop new vaccines every year, but it could take over 6 months to develop a new vaccine that matches the new virus. In a pandemic......
Development of Robot Bacteriophages with CRISPER-Cas9 Technology iNtRON’s PHAGERUS® Technology iNtRON’s PHAGERUS® technology discovered the applicability of bacteriophage as a virus neutralizing vaccine, and has secured a number of related core technologies from late 2018. Based on this, we are actively investing in PHAGERUS® by launching......
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.